Skip to content
10-K

Annual Report

PharmaCyte Biotech, Inc. PMCB

0001683168-25-005821

← back to feed
Filed
Aug 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Aug 4, 2025 6.8M sh
Shares Diluted FY 2025 · Apr 30, 2025 7.33M sh
Shares Diluted FY 2025 · Apr 30, 2024 9.58M sh
Stock Repurchased FY 2025 · Apr 30, 2025 $2.54M
Stock Repurchased FY 2025 · Apr 30, 2024 $28.2M
Operating Cash Flow FY 2025 · Apr 30, 2025 −$2.98M
Operating Cash Flow FY 2025 · Apr 30, 2024 −$2.15M
Cash And Equivalents FY 2025 · Apr 30, 2025 $15.17M
Cash And Equivalents FY 2025 · Apr 30, 2024 $50.18M
Stockholders Equity FY 2025 · Apr 30, 2025 $51.89M
Stockholders Equity FY 2025 · Apr 30, 2024 $27.65M
Stockholders Equity FY 2025 · Apr 30, 2023 $72.69M
Current Liabilities FY 2025 · Apr 30, 2025 $2.91M
Current Liabilities FY 2025 · Apr 30, 2024 $7.42M
Total Liabilities FY 2025 · Apr 30, 2025 $3.28M
Total Liabilities FY 2025 · Apr 30, 2024 $20.39M
Current Assets FY 2025 · Apr 30, 2025 $22.38M
Current Assets FY 2025 · Apr 30, 2024 $50.44M
Total Assets FY 2025 · Apr 30, 2025 $55.17M
Total Assets FY 2025 · Apr 30, 2024 $59.9M
Eps Diluted FY 2025 · Apr 30, 2025 $3.19
Eps Diluted FY 2025 · Apr 30, 2024 −$1.80
Eps Basic FY 2025 · Apr 30, 2025 $3.19
Eps Basic FY 2025 · Apr 30, 2024 −$1.80
Rd Expense FY 2025 · Apr 30, 2025 $438.42K
Rd Expense FY 2025 · Apr 30, 2024 $407.43K
Net Income FY 2025 · Apr 30, 2025 $30.66M
Net Income FY 2025 · Apr 30, 2024 $333.76K
Operating Income FY 2025 · Apr 30, 2025 −$4.38M
Operating Income FY 2025 · Apr 30, 2024 −$8.52M
Revenue FY 2025 · Apr 30, 2025 $0
Revenue FY 2025 · Apr 30, 2024 $0